{"id":"W3012254007","doi":"10.1177/2055217320911939","title":"An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability","year":2020,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal - Experimental Translational and Clinical","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Allergan; EMD Serono; Genentech; MedDay Pharmaceuticals; Sanofi; Bayer HealthCare; Chugai Pharmaceutical; Mallinckrodt Pharmaceuticals; Acorda Therapeutics; Mylan; TG Therapeutics; Sanofi Genzyme; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Biogen; Celgene; University of Texas Health Science Center at Houston","keywords":"Ocrelizumab; Medicine; Expanded Disability Status Scale; Multiple sclerosis; Placebo; Internal medicine; Interferon beta-1a; Oncology; Clinical trial; Physical therapy; Immunology; Pathology; Rituximab; Alternative medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000638614,0.0003080031,0.001068685,0.0001408247,0.0002146899,0.00003202841,0.0002714058,0.0001218086,0.0001142693],"category_scores_gemma":[0.0005332029,0.000183857,0.0004600868,0.001068194,0.001310538,0.0003211684,0.00007572745,0.0005786855,7.276404e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007483893,"about_ca_system_score_gemma":0.0001444931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001164828,"about_ca_topic_score_gemma":0.0002326714,"domain_scores_codex":[0.9959321,0.0005716222,0.001340769,0.0005441159,0.001290317,0.0003210938],"domain_scores_gemma":[0.9971647,0.00118813,0.000421575,0.0003619484,0.0003396744,0.0005240254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01341221,0.005327888,0.9641595,0.00003692245,0.00127091,0.000001133773,0.001655436,0.0006377893,0.01188481,0.000005285202,0.000006881302,0.001601243],"study_design_scores_gemma":[0.02501273,0.002463062,0.9602889,0.0002991517,0.0005128846,7.869497e-7,0.001088275,0.005791588,0.004340117,0.000001686578,0.00000559612,0.0001952512],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979243,0.0002256873,0.0001156689,0.0006875971,0.00003213151,0.0007948275,0.0001907835,0.00001578475,0.00001317215],"genre_scores_gemma":[0.9978713,0.0001098624,0.001658389,0.0001644075,0.00007943184,0.00002538909,0.0000610414,0.00002977199,4.207936e-7],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01160053,"threshold_uncertainty_score":0.7497469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1264345621215076,"score_gpt":0.345705107309352,"score_spread":0.2192705451878444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}